{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:20:56Z","timestamp":1778041256791,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00280-016-3009-7","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T15:27:14Z","timestamp":1458833234000},"page":"973-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced\/refractory cancers"],"prefix":"10.1007","volume":"77","author":[{"given":"Muhammad R.","family":"Khawaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpa M.","family":"Nick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinu","family":"Madhusudanannair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lacey M.","family":"McQuinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaan S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"issue":"5","key":"3009_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"M-A Bjornsti","year":"2004","unstructured":"Bjornsti M-A, Houghton PJ (2004) The tor pathway: a target for cancer therapy. Nat Rev Cancer 4(5):335\u2013348","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3009_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"J Carew","year":"2011","unstructured":"Carew J, Kelly K, Nawrocki S (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6(1):17\u201327. doi:\n                    10.1007\/s11523-011-0167-8","journal-title":"Target Oncol"},{"issue":"1","key":"3009_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10549-010-0763-9","volume":"123","author":"M Zakikhani","year":"2010","unstructured":"Zakikhani M, Blouin M-J, Piura E, Pollak M (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123(1):271\u2013279. doi:\n                    10.1007\/s10549-010-0763-9","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"3009_CR4","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","volume":"66","author":"M Zakikhani","year":"2006","unstructured":"Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66(21):10269\u201310273. doi:\n                    10.1158\/0008-5472.can-06-1500","journal-title":"Cancer Res"},{"issue":"22","key":"3009_CR5","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","volume":"67","author":"RJO Dowling","year":"2007","unstructured":"Dowling RJO, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67(22):10804\u201310812. doi:\n                    10.1158\/0008-5472.can-07-2310","journal-title":"Cancer Res"},{"issue":"9","key":"3009_CR6","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-09-2229","volume":"16","author":"E Rozengurt","year":"2010","unstructured":"Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between insulin\/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16(9):2505\u20132511. doi:\n                    10.1158\/1078-0432.ccr-09-2229","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3009_CR7","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1158\/0008-5472.CAN-09-0418","volume":"69","author":"K Kisfalvi","year":"2009","unstructured":"Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69(16):6539\u20136545. doi:\n                    10.1158\/0008-5472.can-09-0418","journal-title":"Cancer Res"},{"issue":"7503","key":"3009_CR8","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"JMM Evans","year":"2005","unstructured":"Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304\u20131305. doi:\n                    10.1136\/bmj.38415.708634.F7","journal-title":"BMJ"},{"issue":"2","key":"3009_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","volume":"29","author":"SL Bowker","year":"2006","unstructured":"Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2):254\u2013258. doi:\n                    10.2337\/diacare.29.02.06.dc05-1558","journal-title":"Diabetes Care"},{"issue":"5","key":"3009_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.2337\/db14-1132","volume":"64","author":"V Cifarelli","year":"2015","unstructured":"Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, Hursting SD (2015) Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms. Diabetes 64(5):1632\u20131642. doi:\n                    10.2337\/db14-1132","journal-title":"Diabetes"},{"issue":"6","key":"3009_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4161\/cc.8.6.7933","volume":"8","author":"IN Alimova","year":"2009","unstructured":"Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD, Salvesen HB (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8(6):909\u2013915","journal-title":"Cell Cycle"},{"issue":"20","key":"3009_CR12","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","volume":"27","author":"S Jiralerspong","year":"2009","unstructured":"Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung M-C, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297\u20133302. doi:\n                    10.1200\/jco.2009.19.6410","journal-title":"J Clin Oncol"},{"issue":"22","key":"3009_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281. doi:\n                    10.1056\/NEJMoa066838","journal-title":"N Engl J Med"},{"issue":"2","key":"3009_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10637-010-9570-8","volume":"30","author":"M MacKenzie","year":"2012","unstructured":"MacKenzie M, Ernst S, Johnson C, Winquist E (2012) A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs 30(2):647\u2013652. doi:\n                    10.1007\/s10637-010-9570-8","journal-title":"Invest New Drugs"},{"issue":"8","key":"3009_CR15","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00125-006-0316-2","volume":"49","author":"DM Nathan","year":"2006","unstructured":"Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 49(8):1711\u20131721. doi:\n                    10.1007\/s00125-006-0316-2","journal-title":"Diabetologia"},{"issue":"5","key":"3009_CR16","first-page":"1627","volume":"32","author":"H Liu","year":"2012","unstructured":"Liu H, Scholz C, Zang C, Schefe JH, Habbel P, A-c Regierer, Schulz C-O, Possinger K, Eucker J (2012) Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32(5):1627\u20131637","journal-title":"Anticancer Res"},{"issue":"4","key":"3009_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/cncr.28414","volume":"120","author":"HJ Mackay","year":"2014","unstructured":"Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, Werner HMJ, Trovik J, Akslen LA, Salvesen HB, Tu D, Oza AM (2014) Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 120(4):603\u2013610. doi:\n                    10.1002\/cncr.28414","journal-title":"Cancer"},{"issue":"8","key":"3009_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","volume":"33","author":"BM Slomovitz","year":"2015","unstructured":"Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL (2015) Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33(8):930\u2013936. doi:\n                    10.1200\/jco.2014.58.3401","journal-title":"J Clin Oncol"},{"key":"3009_CR19","unstructured":"Soliman P (2015) A phase II, single-arm study of RAD001 (everolimus), letrozole, and metformin in patients with advanced or recurrent endometrial carcinoma. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01797523?term=everolimus%2C+letrozole%2C+metformin&rank=1&show_desc=Y#desc\n                    \n                  . Accessed 11 April 2015"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3009-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3009-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:23:28Z","timestamp":1589628208000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3009-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3009"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3009-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]},"assertion":[{"value":"4 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was funded by the National Cancer Institute at the National Institute of Health (Award Number P30CA016672). The authors declare that they have no relevant conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}